<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00973128</url>
  </required_header>
  <id_info>
    <org_study_id>GMCSFAntimonyCL</org_study_id>
    <nct_id>NCT00973128</nct_id>
  </id_info>
  <brief_title>Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis</brief_title>
  <acronym>GMCSFSbv</acronym>
  <official_title>Reduced Doses of Antimony Plus Recombinant Human GM-CSF Compared With Antimony in Standard Doses for Cutaneous Leishmaniasis: a Randomized, Single-blind, Placebo-controlled, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitário Professor Edgard Santos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado da Bahia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitário Professor Edgard Santos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study was designed as a randomized, single blind, placebo-controlled, study to
      evaluate the effect of 400 µg of recombinant human GM-CSF applied intralesionally and
      associated with half of the total dose of antimony in a reduced time schedule (20mgSbV/Kg/d
      for 10 days) as compared to the full dose of antimony (20mgSbV/Kg/d for 20 days) to treat
      cutaneous leishmaniasis ulcers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, single blind placebo-controlled study in which the groups were selected
      from the cases presenting to the health post. The inclusion criteria were: age between 15 and
      50 years, of either sex, diagnosis of cutaneous leishmaniasis of less than 60 days. The
      diagnostic criteria were the presence of a typical single cutaneous ulcer, localized on lower
      limbs, and a positive delayed type hypersensitivity test (DTH or Montenegro skin test) to
      Leishmania antigen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rate or complete cicatrization of the ulcer</measure>
    <time_frame>3 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial cure rate or complete cicatrization of the ulcer.</measure>
    <time_frame>2 months after treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: Cutaneous leishmaniasis patients randomized in Corte to receive antimony (20mg/daily for 10 days) plus GM-CSF Treatment: antimony (20mg/daily for 10 days) plus GM-CSF (400 µg, divided in two doses a week apart)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2: antimony in standard dose plus saline administered in an identical fashion to the GM-CSF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GMCSF plus Antimony reduced dose</intervention_name>
    <description>400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Sargramostim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meglumine antimoniate</intervention_name>
    <description>20mg/daily for 20 days</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>pentavalent antimony</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 15 and 50 years

          -  Either gender

          -  Diagnosis of cutaneous leishmaniasis

          -  Less than 60 days of disease

        Exclusion Criteria:

          -  Any history of prior anti-leishmania therapy

          -  Negative parasitology (aspirate/smear)or negative Montenegro test

          -  Pregnancy

          -  Age below 15 and above 50 years

          -  Other associated acute or chronic illnesses

          -  History of allergy to GM-CSF and/or antimony

          -  HIV, HTLV-1 infections or diabetes

          -  Administrative reasons:

          -  Lack of ability or willingness to give informed consent (patient and/or parent / legal
             representative)

          -  Anticipated non-availability for study visits/procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roque P Almeida, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitário Prof Edgard Santos-UFBA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Post of Corte de Pedra</name>
      <address>
        <city>Valença</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>September 8, 2009</last_update_submitted>
  <last_update_submitted_qc>September 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Roque Pacheco de Almeida</name_title>
    <organization>Hospital Universitário Prof. Edgard Santos</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meglumine antimoniate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

